Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
The discussants examined the role of value-based care models in optimizing management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Dr Ebot-Tar discussed how such agreements can facilitate access to innovative therapies while aligning costs to outcomes. She shared an example of analyzing real-world chimeric antigen receptor T-cell therapy episode costs and durability to identify opportunities to potentially improve value. Ongoing engagement between payers and research centers provides insights to inform coverage decisions for emerging therapies with still-evolving data. Dr Haumschild concurred that direct provider input helps plans design appropriate medical policies for specialized conditions like Ph+ ALL.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen